<DOC>
	<DOCNO>NCT00003344</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high energy x-rays damage tumor cell . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining radiation therapy chemotherapy may kill tumor cell . PURPOSE : Phase I/II trial study effectiveness radiation therapy plus irinotecan treating patient colon cancer recurrent remove surgically .</brief_summary>
	<brief_title>Radiation Therapy Plus Irinotecan Treating Patients With Colon Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) weekly irinotecan result acceptable level toxicity give combination concurrent external beam radiation therapy . II . Determine objective response rate patient dose level MTD . OUTLINE : Patients receive irinotecan IV 90 minute begin within 24 hour radiotherapy day 1 , 8 , 15 , 22 . External beam radiotherapy administer 5 day per week 5.5-6 week start day 1 concurrent chemotherapy . Cohorts 3-6 patient treat maximum tolerate dose ( MTD ) determine . The MTD define dose level incidence dose limit toxicity great one-third patient treat dose level . Once MTD determine , additional patient receive irinotecan dose level MTD external beam radiation therapy treatment schedule . Patients follow 4 week treatment , every 3 month 2 year , every 6 month 3 additional year . PROJECTED ACCRUAL : Approximately 3-24 patient accrued Phase I portion study . Approximately 15-25 patient accrue Phase II portion study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm unresectable , incompletely resect gross residual disease , locally recurrent large bowel carcinoma confine site within abdomen pelvis All disease must encompassable within single radiotherapy port No evidence uncontrolled metastatic disease outside plan radiotherapy port PATIENT CHARACTERISTICS : Age : 18 Performance status : CALGB 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin great 2.0 mg/dL Renal : Not specify Cardiovascular : No history significant myocardial disease No New York Heart Association class III IV disease No unstable angina No myocardial infarction past 4 month Other : No significant infection coexistent medical condition would preclude protocol therapy Maintain adequate oral nutrition intake ( least 1,200 calorie estimate per day ) No great 6 bowel movement per day prior treatment No significant nausea emesis optimal antiemetic therapy Not pregnant nursing Effective contraception require fertile patient PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior irinotecan Endocrine therapy : Not specify Radiotherapy : No prior abdominal pelvic radiotherapy Surgery : At least 3 week since laparotomy laparoscopic procedure without resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>